Results 31 to 40 of about 21,178 (234)

Diabetes is predominantly an intestinal disease

Indian Journal of Endocrinology and Metabolism, 2013
Diabetes mellitus (DM) is a chronic, progressive, medically incurable disease and is poorly controlled in a vast majority, in spite of tremendous advancements in pharmacotherapy. Altered gut microbiome can predict diabetes. There is strong and consistent
Debmalya Sanyal
doaj   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects

Frontiers in Endocrinology
IntroductionIncretin-based drugs are extensively utilized in the treatment of type 2 diabetes (T2D), with remarkable clinical efficacy. These drugs were developed based on findings that the incretin effect is reduced in T2D.
Akihiro Hamasaki, Akihiro Hamasaki, Norio Harada, Atsushi Muraoka, Shunsuke Yamane, Erina Joo, Kazuyo Suzuki, Nobuya Inagaki   +7 more
doaj   +1 more source

Identification of Kunitz inhibitor from Cassia obtusifolia L. and its inhibitory effect against Pieris rapae proteases

浙江大学学报. 农业与生命科学版, 2008
A trypsin inhibitor from Cassia obtusifolia seeds, a well known Chinese herb, was isolated to apparent homogeneity by a combination of distilled water extraction, ammonium sulfate precipitation, Sepharose 4B-trypsin affinity and Sephadex G-75 ...
LIAO Hai, REN Wei, ZHAO Xiao-jun, DU Lin-fang   +3 more
doaj   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras Serrano, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Cloning and Tissue Expression of gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide (GIP) in Pigs

四川大学学报. 自然科学版, 2017
The gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide (GIP) shows the inhibitory effect on gastric acid secretion and incretin action. The aim of this study is to analyze the cDNA sequence of the pig GIP (pGIP) gene, and further
CHENG Shao-Chen, ZHANG Jian-Nan, ZHONG Yu, LI Juan, WANG Ya-Jun   +4 more
doaj  

Emerging concepts in obesity management: focus on glucagon receptor agonist combinations

Drugs in Context
The global rise in obesity and its associated health risks has driven the need for more effective pharmacological treatments. Glucagon receptor (GCGR)-based multi-agonist drugs are emerging as promising treatments for obesity, with several in advanced ...
Sarah L Anderson
doaj   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure

Clinical Pharmacology &Therapeutics, EarlyView.
This study investigated genetic determinants of the pharmacokinetics of the CYP2C8 index drugs repaglinide and gemfibrozil, and their interaction in healthy participants. Sequencing data from a study with montelukast revealed a novel functional CYP2C8 allele (rs2071426, CYP2C8*19), predicted to create an intronic splice donor site.
Anssi J. H. Mykkänen, Päivi Hirvensalo, Kathrin Klein, Dorota Kaminska, Markus Grube, Tuija Tapaninen, Johanna I. Kiiski, Mikko Neuvonen, Ville T. Männistö, Jussi Pihlajamäki, Mladen Tzvetkov, Matthias Schwab, Aleksi Tornio, Janne T. Backman, Mikko Niemi   +14 more
wiley   +1 more source

Current State of Pharmacotherapy in Obesity

The Korean Journal of Gastroenterology
The prevalence of obesity with various complications is increasing rapidly in Korea. Although lifestyle modification is fundamental in obesity treatment, more effective treatment tools are required.
Won Jun Kim
doaj   +1 more source